top of page

Profile

Join date: Jan 17, 2025

About

0 likes received
0 comments received
0 best answers

Biparatopic receptor-based bispecific ADCs (Antibody-Drug Conjugates) are an advanced class of therapeutics designed to target and destroy cancer cells with high specificity and potency. They integrate several cutting-edge biological technologies, including bispecific antibodies, biparatopic targeting, and the cytotoxic effects of ADCs.

Smith Gemini

More actions
bottom of page